Sodium-glucose cotransporter-2 inhibitor (SGLT2-I)gained intense interest in the search for the mechanisms responsible for theirbeneficial effects in patients with and without diabetes mellitus (DM) [22], although the precisemechanisms remain unclear. This evidence concerns the gene SLC5A2 and diabetes mellitus.